The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 05, 2019

Filed:

Nov. 14, 2013
Applicant:

Daniel Offen, Kfar HaRoe, IL;

Inventors:

Chen Benkler, Tel-Aviv, IL;

Daniel Offen, Kfar HaRoe, IL;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 38/44 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61K 38/43 (2006.01);
U.S. Cl.
CPC ...
A61K 38/44 (2013.01); A61K 38/1709 (2013.01); A61K 38/43 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0318 (2013.01); A61K 48/00 (2013.01); C12N 2740/15043 (2013.01); C12Y 104/01003 (2013.01);
Abstract

A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.


Find Patent Forward Citations

Loading…